2型糖尿病合并心房颤动的危险因素分析

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (630 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the risk factors of atrial fibrillation (AF) in type 2 diabetes mellitus (T2DM). Methods From January 2016 to January 2018, 530 cases of T2DM patients (control group), 533 patients with T2DM combined with AF (T2DM combined with AF group) admitted to the Affiliated Hospital of Xuzhou Medical University were selected, 533 patients with T2DM combined with AF were divided into two subgroups, including 220 patients with paroxysmal AF (T2DM combined with PAF group) and 313 patients with non-paroxysmal AF (T2DM combined with NPAF group). Relevant indicators were collected for univariate anova and Logistic regression analysis, influencing factors were screened out, and their predictive value was analyzed by ROC. Results Univariate analysis showed that there were statistically significant differences in the levels of uric acid, blood glucose, glycosylated hemoglobin, bilirubin, low-density lipoprotein and cholesterol between the control group and T2DM combined with AF group (P ＜ 0.05). Logistic regression analysis showed that uric acid (OR = 1.005, P ＜ 0.05) and glycosylated hemoglobin (OR = 1.398, P ＜ 0.05) were risk factors for the occurrence of AF in T2DM. Total bilirubin (OR = 0.929, P ＜ 0.05), low-density lipoprotein (OR = 0.285, P ＜ 0.05) and cholesterol (OR = 0.610, P ＜ 0.05) were protective factors for the occurrence of AF in T2DM patients. ROC curve analysis showed that the above indicators have certain predictive value for the occurrence of atrial fibrillatione. Conclusion Uric acid and glycosylated hemoglobin are independent risk factors for atrial fibrillation in patients with T2DM, while total bilirubin, low-density lipoprotein and cholesterol are the protective factors of atrial fibrillation.

Key words： Diabetes Atrial fibrillation Uric acid Glycosylated hemoglobin Serum lipid

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	QIU Na LING Hongwei ZHOU Dongmei SUN Juan YING Changjiang LI Wei

Cite this article:

QIU Na LING Hongwei ZHOU Dongmei SUN Juan YING Changjiang LI Wei. Risk factors for type 2 diabetes mellitus with atrial fibrillation[J]. 中国医药导报, 2019, 16(11): 105-108.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I11/105

[1] Stewart S，Hart CL，Hole DJ，et al. A population-based study of the long-term risks associated with atrial fibrillation：20-year follow-up of the Renfrew/Paisley study [J]. Am J Med，2002，113（5）：359-364.
[2] Huxley RR，Alonso A，Lopez FL，et al. Type 2 diabetes，glucose homeostasis and incident atrial fibrillation：the Atherosclerosis Risk in Communities Study [J]. Heart，2012，98（2）：133-138.
[3] Huxley RR，Filion KB，Konety S，et al. Meta-analysis of Cohort and Case-Control Studies of Type-2 Diabetes Mellitus and Risk of Atrial Fibrillation [J]. Am J Cardiol，2011，108（1）：56-62.
[4] Du X，Ninomiya T，de Galan B，et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation：results of the ADVANCE study [J]. Eur Heart J，2009，30（9）：1128-1135.
[5] 中国医师协会心律学专业委员会心房颤动防治专家工作委.心房颤动：目前的认识和治疗建议-2015[J].中华心律失常学杂志，2015，19（5）：377-434.
[6] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2013年版）[J].中华内分泌代谢杂志，2014，30（10）：893-942.
[7] Culleton BF，Larson MG，Kannel WB，et al. Serum uric acid and risk for cardiovascular disease and death：the Framingham Heart Study [J]. Ann Intern Med，1999，131（1）：7-13.
[8] Kawasoe S，Kubozono T，Yoshifuku S，et al. Uric Acid Level and Prevalence of Atrial Fibrillation in a Japanese General Population of 285 882 [J]. Circ J，2016，80（12）：2453-2459.
[9] Tamariz L，Hernandez F，Bush A，et al. Association between serum uric acid and atrial fibrillation：a systematic review and meta-analysis [J]. Heart Rhythm，2014，11（7）：1102.
[10] Kang DH，Park SK，Lee IK，et al. Uric acid-induced C-reactive protein expression：implication on cell proliferation and nitric oxide production of human vascular cells [J]. J Am Soc Nephrol，2005，16（12）：3553-3562.
[11] Maharani N，Kuwabara M，Hisatome I. Hyperuricemia and Atrial Fibrillation [J]. Int Heart J，2016，57（4）：395.
[12] Saito S，Teshima Y，Fukui A，et al. Glucose fluctuations increase the incidence of atrial fibrillation in diabetic rats [J]. Cardiovasc Res，2014，104（1）：5-14.
[13] Raposeirasroubín S，Barreiroparda C，Roubíncami?觡a F，et al. Advanced glycation end products：a mysterious shadow beyond the relationship between HbA1c and atrial fibrillation [J]. Int J Cardiol，2012，157（3）：441.
[14] Vítek L，Jirsa M，Brodanová M，et al. Gilbert syndrome and ischemic heart disease：a protective effect of elevated bilirubin levels [J]. Atherosclerosis，2002，160（2）：449-456.
[15] Dekker D，Dorresteijn MJ，Pijnenburg M，et al. The Bilirubin-Increasing Drug Atazanavir Improves Endothelial Function in Patients With Type 2 Diabetes Mellitus [J]. Arterioscler Thromb Vasc Biol，2011，31（2）：458-463.
[16] Iguchi Y，Kimura K，Aoki J，et al. Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan：analysis of 41，436 non-employee residents in Kurashiki-city [J]. Circ J，2008，72（6）：909-913.
[17] Watanabe H, Aizawa Y. Letter by Watanabe and Aizawa regarding article，"Blood lipid levels，lipid-lowering medications，and the incidence of atrial fibrillation：the Atherosclerosis Risk in Communities （ARIC） Study" [J]. Circ Arrhythm Electrophysiol，2012，5（1）：155.
[18] Watanabe H，Tanabe N，Yagihara N，et al. Association between lipid profile and risk of atrial fibrillation [J]. Circ J，2011，75（12）：2767-2774.
[19] Díaz-Peromingo JA，Albán-Salgado A，García-Suárez F，et al. Lipoprotein（a） and lipid profile in patients with atrial fibrillation [J]. Med Sci Monit，2006，12（3）：CR122-CR125.
[20] Suzuki S. “Cholesterol paradox”in atrial fibrillation [J]. Circ J，2011，75（12）：2749-2750.